
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Thyroid Cancer Diagnostics Market**

According to Intelli, the U.S. Thyroid Cancer Diagnostics Market size was valued at USD 1,037.42 Million in 2024 and is projected to reach USD 1,554.41 Million by 2032, growing at a CAGR of 5.71% from 2025 to 2032.



Thyroid cancer diagnostics is a critical area of healthcare that involves advanced techniques and cutting-edge technologies to identify and assess malignant growths in the thyroid gland. The thyroid, a butterfly-shaped gland in the neck, is responsible for producing hormones that regulate metabolism, heart rate, and body temperature. Although thyroid cancer is relatively rare compared to other cancers, its incidence has been rising, making early detection and precise diagnosis essential for effective treatment and improved patient outcomes. The diagnostic process for thyroid cancer is multifaceted, involving a combination of clinical evaluation, imaging tests, and biopsy procedures. One of the most common imaging methods is ultrasound, which helps physicians visualize the thyroid gland's structure and detect abnormal nodules or growths. Fine needle aspiration (FNA) biopsy is another cornerstone technique, allowing for the collection of tissue samples from suspicious nodules to determine whether they are benign or malignant. Advances in molecular testing and genetic profiling are increasingly being used to refine diagnosis, offering insights into the genetic mutations and biomarkers that drive thyroid cancer, thereby facilitating personalized treatment approaches. The role of diagnostic technologies in thyroid cancer is evolving with the integration of artificial intelligence (AI) and machine learning (ML), enhancing the accuracy and speed of detection. AI algorithms can now assist in analyzing ultrasound images and pathology slides, helping clinicians make more informed decisions. Moreover, advances in blood-based biomarkers are opening new doors for non-invasive diagnostics, providing a promising avenue for early detection, monitoring, and prognostic assessment of thyroid cancer. With ongoing research and advancements in diagnostic tools, the landscape of thyroid cancer detection is becoming more precise, leading to better survival rates and quality of life for patients.

**U.S. Thyroid Cancer Diagnostics Market Definition**

The U.S. thyroid cancer diagnostics market encompasses the array of medical technologies and procedures utilized to detect and evaluate thyroid cancer, a malignancy originating in the thyroid gland. This market includes diagnostic modalities such as imaging A close-up of hands holding a tablet and a pen

Description automatically generatedtechniques (e.g., ultrasound, CT scans, MRI), biopsy methods (notably fine needle aspiration), blood tests (e.g., TSH and thyroglobulin levels), and advanced molecular diagnostics (e.g., genetic testing and liquid biopsy). These diagnostic tools are utilized in a range of healthcare environments, such as hospitals, specialized cancer diagnostic centers, and research institutions, to enable early detection, precise diagnosis, and tailored treatment strategies for patients.

**U.S. Thyroid Cancer Diagnostics Market Overview**

The U.S. thyroid cancer diagnostics market is experiencing significant growth, driven by a confluence of factors that enhance early detection, diagnostic accuracy, and treatment personalization. One of the primary drivers is the rising incidence of thyroid cancer, particularly papillary carcinoma, the most prevalent form, highlighting the growing demand for timely and precise diagnostic solutions. This trend has intensified the focus on early detection, which is critical for improving treatment outcomes. Rapid advancements in diagnostic technologies have significantly improved the accuracy and efficiency of thyroid cancer detection. Innovations such as molecular diagnostic assays, artificial intelligence-powered imaging systems, and the development of novel biomarkers are transforming the diagnostic landscape, allowing for earlier and more personalized detection strategies. Complementing these advancements is the strength of the U.S. healthcare system, which offers widespread access to cutting-edge diagnostic facilities through a network of highly specialized hospitals and cancer centers. Moreover, supportive government policies, expanded insurance coverage, and proactive public health initiatives are making diagnostics more accessible and affordable for patients. National awareness campaigns have also played a crucial role in educating the population about the importance of routine screenings, thereby increasing the rate of early diagnosis.

**U.S. Thyroid Cancer Diagnostics Market Segmentation**

The U.S. thyroid cancer diagnostics market can be segmented based on various factors, such as diagnostic type, technology, and end-user.

**U.S. Thyroid Cancer Diagnostics Market, By Diagnostic Type**

* A close-up of hands holding a tablet and a pen

  Description automatically generated**Imaging Techniques**
* **Biopsy**
* **Molecular Diagnostics**
* **Blood Tests**

The U.S. thyroid cancer diagnostics market is primarily driven by four key diagnostic types including imaging techniques, biopsy, molecular diagnostics, and blood tests, each playing a crucial role in early detection and accurate diagnosis. Imaging techniques, particularly ultrasound, dominate the market, holding a significant market share due to their non-invasive nature and high accuracy in detecting thyroid nodules. Biopsy, especially fine needle aspiration (FNA), is another cornerstone, accounting for a substantial portion of the market as it provides definitive results through the extraction and examination of tissue samples. Molecular diagnostics is gaining traction, contributing a rapidly growing share, driven by innovations in genetic testing and next-generation sequencing (NGS), which enable precise classification of thyroid cancer types and personalized treatment planning. Finally, blood tests, including markers like thyroglobulin and calcitonin, are widely used in monitoring thyroid function and assessing cancer recurrence, contributing a steady share to the market.

**U.S. Thyroid Cancer Diagnostics Market, By Technology**

* **Ultrasound Imaging**
* **Liquid Biopsy**
* **Next-Generation Sequencing**
* **Artificial Intelligence**

The U.S. thyroid cancer diagnostics market, segmented by technology, showcases a dynamic interplay of traditional and emerging diagnostic innovations that are reshaping clinical practices. Ultrasound imaging holds the largest market share, remaining the first-line diagnostic tool due to its accessibility, cost-effectiveness, and ability to accurately detect and evaluate thyroid nodules in real time. However, next-generation sequencing is rapidly transforming the landscape, capturing an increasing share by enabling in-depth genetic profiling and identifying specific mutations such as BRAF and RAS, which are critical for personalized treatment planning. Liquid biopsy, although still an emerging segment, is gaining momentum for its non-invasive approach to detecting circulating A close-up of hands holding a tablet and a pen

Description automatically generatedtumor DNA, offering promising potential for early diagnosis, treatment monitoring, and recurrence detection. Meanwhile, AI is revolutionizing diagnostic precision and efficiency, particularly in image analysis, by enhancing the accuracy of ultrasound interpretation and streamlining clinical workflows. Together, these technologies reflect a shift toward more personalized, precise, and less invasive diagnostic solutions in the thyroid cancer space, with NGS and AI expected to drive the next phase of market growth.

**U.S. Thyroid Cancer Diagnostics Market, By End-User**

* **Hospitals**
* **Diagnostic Laboratories**
* **Cancer Research Institutes**

The U.S. thyroid cancer diagnostics market, segmented by end-user, reflects a diverse ecosystem of healthcare providers playing distinct yet complementary roles in the diagnostic pathway. Hospitals represent the largest end-user segment, accounting for a dominant market share due to their integrated infrastructure, wide range of diagnostic services, and ability to manage large patient volumes for both initial assessments and ongoing monitoring. Diagnostic laboratories follow closely, offering specialized testing services such as fine needle aspiration cytology, molecular diagnostics, and genetic testing. Cancer research institutes, though a smaller segment in terms of volume, are pivotal in driving innovation. They focus on developing and validating new diagnostic biomarkers, techniques, and AI-driven tools, contributing significantly to the evolution of thyroid cancer detection.

**Key Players**

The “U.S. thyroid cancer diagnostics market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., GE Healthcare, Koninklijke Philips N.V., Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Becton, Dickinson and Company, Guardant Health Inc., Myriad Genetics Inc., Novartis International AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Bayer AG, Sanofi S.A., AstraZeneca plc, Toshiba Corporation ​among others. Our market analysis also entails a A close-up of hands holding a tablet and a pen

Description automatically generatedsection solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In 2025, the FDA expanded the use of cabozantinib to treat patients aged 12 and older with previously treated, unresectable, or metastatic well-differentiated thyroid cancer that no longer responds to radioactive iodine.
* In 2024, the FDA fully approved selpercatinib for adults and children aged two and older with advanced or metastatic RET fusion–positive thyroid cancer.
* An innovation in 2024 was the development of advanced imaging agents like ^68Ga-Trivehexin, which significantly improved thyroid cancer staging.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. thyroid cancer diagnostics market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape U.S. thyroid cancer diagnostics market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF** **U.S. THYROID CANCER DIAGNOSTICS MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. THYROID CANCER DIAGNOSTICS MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE**

5.1 Overview

A close-up of hands holding a tablet and a pen

Description automatically generated5.2 Imaging Techniques

5.3 Biopsy

5.4 Molecular Diagnostics

5.5 Blood Tests

**6 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY**

6.1 Overview

6.2 Ultrasound Imaging

6.3 Liquid Biopsy

6.4 Next-Generation Sequencing

6.5 Artificial Intelligence

**7** **U.S. THYROID CANCER DIAGNOSTICS MARKET, BY END-USER**

7.1 Overview

7.2 Hospitals

7.3 Diagnostic Laboratories

7.4 Cancer Research Institutes

1. **U.S. THYROID CANCER DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
2. A close-up of hands holding a tablet and a pen

   Description automatically generated**CMPANY PROFILES**

**9.1 Abbott Laboratories**

* + 1. Overview
    2. Financial Performance
    3. roduct Outlook
    4. Key developments
  1. **Thermo Fisher Scientific Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Siemens Healthineers AG**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **F. Hoffmann-La Roche Ltd.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **GE Healthcare**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. A close-up of hands holding a tablet and a pen

        Description automatically generatedKey developments
  5. **Koninklijke Philips N.V.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Agilent Technologies Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Illumina Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **PerkinElmer Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Becton, Dickinson and Company**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. A close-up of hands holding a tablet and a pen

        Description automatically generatedKey developments
  3. **Guardant Health Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Myriad Genetics Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Novartis International AG**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Bristol-Myers Squibb Company**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Eli Lilly and Company**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  8. A close-up of hands holding a tablet and a pen

     Description automatically generated**Bayer AG**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  9. **Sanofi S.A.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  10. **AstraZeneca plc**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments
  11. **Toshiba Corporation**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. A close-up of hands holding a tablet and a pen

   Description automatically generated**Appendix**

11.1 Related Research